http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Park, Young Soo,Na, Young-Soon,Ryu, Min-Hee,Lee, Chae-Won,Park, Hye Jin,Lee, Ju-Kyung,Park, Sook Ryun,Ryoo, Baek-Yeol,Kang, Yoon-Koo American Society for Clinical Pathology 2015 American journal of clinical pathology Vol.143 No.6
<P><B>Objectives:</B></P><P>Fibroblast growth factor receptor 2 <I>(FGFR2)</I> amplification has been reported to be a target for treatment in gastric cancer. However, an optimal tissue source and method for evaluating <I>FGFR2</I> have yet to be established.</P><P><B>Methods:</B></P><P>Copy numbers were compared by quantitative polymerase chain reaction (qPCR) using frozen vs formalin-fixed, paraffin-embedded (FFPE) tissue and biopsy vs surgical specimens. We correlated the results of qPCR and immunohistochemistry (IHC) with fluorescence in situ hybridization (FISH) using stage IV gastric cancer biopsy specimens and validated the results in surgical specimens.</P><P><B>Results:</B></P><P>FFPE tissues were suitable for qPCR, and biopsy specimens were equivalent to or better than surgical specimens. qPCR and IHC results exhibited an excellent correlation with FISH at eight or more copies by qPCR in any kind of tissue, 5% or more by IHC in biopsy specimens, and 10% or more by IHC in surgical specimens. <I>FGFR2</I> amplification was 6.6% in stage IV gastric cancers, and 42% of these showed heterogeneous amplification and overexpression. IHC indicated a good correlation with FISH even in the heterogeneous cases.</P><P><B>Conclusions:</B></P><P>FFPE biopsy tissues are an adequate source for <I>FGFR2</I> evaluation in gastric carcinomas, and a qPCR-based copy number assay can be used for screening. IHC is also a valid and practical method for evaluating <I>FGFR2</I>, considering frequent heterogeneity.</P>
이석호,이화영,이규택,강인구,최규완,백승운,이종균,이준혁,고광철,이종철,오영륜,현재근,이풍렬,김재준,채종일 대한소화기내시경학회 1999 Clinical Endoscopy Vol.19 No.2
Strongyloidiasis is a parasitic disease caused by Strongyloides stercoralis which exists in two forms : the free living and parasitic forms. It exists in warm, moist climate in areas where there is frequent fecal contamination of the soil. After cutaneous invasion by the filariform larvae, petechial hemorrage, pruritus, papular rashes, edema, and urticaria occur. Infection commonly occurs in the proximal intestine of the gastrointestinal (G-I) tract but may extend from the stomach to the anus. Once the worm is established in the small intestine, the physical findings may include epigastric tenderness to palpation. The mucosal biopsy is an inefficient way of making the diagnosis because the worm is found in the biopsy specimen in only 2% of patients. Gastric strongyloidiasis is rare. We experienced a case of gastric strongyloidiasis diagnosed by the endoscopic biopsy and serologic test for parasite specific IgG antibody by micro-ELISA.
1차 항결핵제 약물이상반응 현황: 단일기관 약물이상사례 보고사례 기반 분석
김현화 ( Hyun Hwa Kim ),문미라 ( Mira Moon ),최나이 ( Nigh Choi ),강동윤 ( Dong Yoon Kang ),채경옥 ( Kyung Ok Chae ),이정실 ( Jungsil Lee ),임재준 ( Jae-joon Lim ),조상헌 ( Sang-heon Cho ),강혜련 ( Hye-ryun Kang ) 대한내과학회 2021 대한내과학회지 Vol.96 No.5
Background/Aims: Tuberculosis has incidence and mortality rates that are among the highest for all communicable diseases. Adverse drug reactions (ADRs) to anti-tubercular drugs are common, and have a major impact on treatment maintenance and prognosis. It is important to understand the characteristics of ADRs and establish a suitable management plan. Methods: We retrospectively reviewed patients with ADRs during treatment with first-line antitubercular drugs such as isoniazid, rifampicin, ethambutol, and pyrazinamide from 2009 to 2018. Age, sex, and total treatment period, and the onset, severity, seriousness, and system organ class of ADRs, were analyzed to understand the characteristics of first-line anti-tubercular drug-related ADRs. Results: A total of 1,606 of 5,482 patients (29.3%) experienced ADRs after administration of first-line anti-tubercular drugs. The incidence of ADRs related to isoniazid, rifampicin, ethambutol, and pyrazinamide was 22.2%, 21.3%, 24.5%, and 29.6%, respectively. A total of 2,098 ADR reports were made (mean of 1.3 ± 0.6 per patient). The rates of mild, moderate, and severe ADRs were 32.4%, 61.1%, and 6.5%, respectively. There were 127 reports (6.1%) of serious ADRs. Skin and appendage disorders were most frequently reported (27.5%), followed by gastrointestinal disorders (17.5%), and liver and biliary system disorders (13.1%). The total treatment period was longer in patients who experienced ADRs (224.0 ± 3.1 days vs. 247.0 ± 4.7 days, p = 0.009). Conclusions: The incidence of ADRs to first-line anti-tuberculosis drugs was 29.3%, and 6.5% were severe ADRS. ADRs prolonged the overall treatment duration, indicating the importance of their detection and management. (Korean J Med 2021;96:421-431)